89bio Inc.

14.53+0.1300+0.90%Vol 1.10M1Y Perf 121.54%
Oct 4th, 2023 16:00 DELAYED
BID13.84 ASK15.21
Open14.29 Previous Close14.40
Pre-Market- After-Market14.82
 - -  0.29 2.00%
Target Price
24.63 
Analyst Rating
Strong Buy 1.10
Potential %
69.51 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-50 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-84 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-70 
Income Ranking
 —    -
Price Range Ratio 52W %
52.52 
Earnings Rating
Market Cap1.10B 
Earnings Date
9th Nov 2023
Alpha0.01 Standard Deviation0.25
Beta0.74 

Today's Price Range

13.9314.71

52W Range

5.2422.93

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.89%
1 Month
-16.83%
3 Months
-23.89%
6 Months
-0.89%
1 Year
121.54%
3 Years
-43.18%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ETNB14.530.13000.90
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
5.60
5.80
0.08
0.13
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.41-0.52-26.83
Q01 2023-0.56-0.543.57
Q04 2022-0.63-0.4823.81
Q03 2022-0.89-0.5735.96
Q02 2022-1.04-1.23-18.27
Q01 2022-1.38-1.268.70
Q04 2021-1.51-1.3013.91
Q03 2021-1.07-1.41-31.78
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Nov 2023
Estimated EPS Next Report-0.50
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.10M
Shares Outstanding75.48K
Shares Float58.80M
Trades Count11.53K
Dollar Volume15.75M
Avg. Volume1.12M
Avg. Weekly Volume1.31M
Avg. Monthly Volume1.12M
Avg. Quarterly Volume923.10K

89bio Inc. (NASDAQ: ETNB) stock closed at 14.53 per share at the end of the most recent trading day (a 0.9% change compared to the prior day closing price) with a volume of 1.10M shares and market capitalization of 1.10B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. 89bio Inc. CEO is Rohan Palekar.

The one-year performance of 89bio Inc. stock is 121.54%, while year-to-date (YTD) performance is 14.14%. ETNB stock has a five-year performance of %. Its 52-week range is between 5.24 and 22.93, which gives ETNB stock a 52-week price range ratio of 52.52%

89bio Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 3.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -56.27%, a ROC of -63.31% and a ROE of -69.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from 89bio Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. 89bio Inc.’s next earnings report date is 09th Nov 2023.

The consensus rating of Wall Street analysts for 89bio Inc. is Strong Buy (1.1), with a target price of $24.63, which is +69.51% compared to the current price. The earnings rating for 89bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

89bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

89bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.51, ATR14 : 0.94, CCI20 : -141.94, Chaikin Money Flow : -0.03, MACD : -0.55, Money Flow Index : 20.11, ROC : -17.05, RSI : 35.38, STOCH (14,3) : 12.12, STOCH RSI : 0.00, UO : 42.98, Williams %R : -87.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 89bio Inc. in the last 12-months were: Atkinson Edward Morrow III (Option Exercise at a value of $16 312), Atkinson Edward Morrow III (Sold 6 250 shares of value $111 938 ), Edward Morrow Atkinson (Option Excercise at a value of $44 400), Edward Morrow Atkinson (Sold 10 000 shares of value $136 000 ), Edward Morrow Iii Atkinson (Option Excercise at a value of $60 713), Hayden Michael (Buy at a value of $993 839), Le-Nguyen Quoc (Sold 0 shares of value $-247 466 ), Le-Nguyen Quoc (Sold 13 683 shares of value $247 799 ), Martins Ryan (Sold 0 shares of value $-9 330 ), Martins Ryan (Sold 27 280 shares of value $388 782 ), Michael Hayden (Buy at a value of $993 839), Palekar Rohan (Sold 0 shares of value $-28 950 ), Palekar Rohan (Sold 30 000 shares of value $540 000 ), Rohan Palekar (Sold 15 000 shares of value $240 000 ), Ryan Martins (Option Excercise at a value of $9 330), Ryan Martins (Sold 27 280 shares of value $388 782 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
9 (90.00 %)
7 (87.50 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.10
Strong Buy
1.13

89bio Inc.

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

CEO: Rohan Palekar

Telephone: +1 415 500-4614

Address: 142 Sansome Street, San Francisco 94104, CA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

Bearish Bullish

55%45%

 

News

Stocktwits